S2.2 aptamer sodium

After conjugation with SiND-Cy5, S2.2 aptamer sodium (100 μM, 32.5 mg, 150 μg/mL^-1, 3.33-250 nM; 5 min, 1.5 h, 12 h, 90 min) enables highly specific and sensitive turn-on fluorescence detection of MUC1 in cell-free samples, with a linear range of 3.33-250 nM and a limit of detection of 1.52 nM, and exhibits reliable performance in spiked human serum^[1].
After conjugation with SiND-Cy5, S2.2 aptamer sodium (0.15-1.02 mg/mL; 24 h) exhibits low cytotoxicity against human breast cancer MCF-7 cells; at concentrations as high as 1.02 mg mL^-1, the cell survival rate remains >90% after 24 h of incubation^[1].
After conjugation with S2.2 aptamer sodium (0.41 mg/mL; 90 min), SiND-Cy5 enables highly specific targeted fluorescence imaging of MUC1-positive human breast cancer MCF-7 cells, and no binding to MUC1-negative MCF-10A cells or Vero cells is detected^[1].
S2.2 aptamer sodium binds to the VNTR region of TA-MUC1 with high affinity (K_d=0.135 nM or 13.6 nM), and exhibits better specificity than the monoclonal antibody C595 (HY-P990831), including the ability to detect single-mutant epitopes^[3].
Conjugation of S2.2 aptamer sodium with Doxorubicin (HY-15142) enhances cell penetration, promotes Doxorubicin (DOX) release, and reduces the IC₅₀ of DOX in MUC1-positive cancer cells^[3].
S2.2 aptamer sodium-miR-29b chimera restores PTEN expression, induces apoptosis in OVCAR-3 ovarian cancer cells, and sensitizes Paclitaxel (HY-B0015)-resistant OVCAR-3 cells to Paclitaxel (PTX)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.